Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | POLG | P54098 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086024 | 0.88 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBABCB11 | |
| SCHEMBL5083010 | 0.72 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBABCB11 | |
| SCHEMBL5080083 | 0.70 | FDPS (0.37) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL5083011 | 0.69 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21126195 | 0.65 | PI4KA (0.64) | FGFR1FGFR4P2RX7PI4KAPI4K2B | |
| SCHEMBL1741386 | 0.64 | TYMP (0.38) | FGFR1FGFR4PI4KAPI4K2BPI4K2A | |
| SCHEMBL12985179 | 0.63 | SLC22A12 (0.36) | DGAT1 | |
| SCHEMBL5106770 | 0.62 | P2RX7 (0.41) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL9545171 | 0.62 | P2RX7 (0.56) | FGFR1FGFR4P2RX7PI4KAPI4K2B | |
| SCHEMBL14175409 | 0.61 | ABCB11 (0.34) | ABCB11POLA1POLGFAPSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | FGFR1 3600/4885FGFR4 2803/4885P2RX7 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.